Summary

Summary of guidance:

• This guideline makes specific recommendations on Alzheimer's disease, dementia with Lewy bodies (DLB), frontotemporal dementia, vascular dementia and mixed dementias, as well as recommendations that apply to all types of dementia. Dementia in Parkinson's disease shares a number of similarities with DLB. Although the evidence base for dementia in Parkinson's disease was not examined specifically in the context of this guideline, the recommendations for DLB may be useful when considering treatments for dementia in Parkinson's disease. NICE has also produced a clinical guideline on Parkinson's disease.
• The dementia guideline incorporates recommendations from the NICE technology appraisal TA217 of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease, published in March 2011.This guidance replaces NICE technology appraisal guidance 111 issued in November 2006 (amended September 2007, August 2009). The amended guidance clarifies the steps healthcare professionals should take when assessing whether Alzheimer's disease is of moderate severity and highlights that clinicians should be mindful of the need to secure equality of access to treatment.
  
  

How to cite NICE mental health guidelines developed by the NCCMH